The share price of INSYS Therapeutics, Inc. [NASDAQ: INSY] inclined by $0.34, presently trading at $0.40. The company’s shares saw 181.69% gains compared to the lowest price in the period of the last 52 weeks, set at $0.14 recorded on 13/06/2019. The last few days have been benevolent to the share price as INSY N/A by during the last week, even though the stock is still N/A by compared to of all time high it touched on . However, the stock had a poor performance during the past 3 months, roughly losing -67.74%, while additionally dropping -94.48% during the last 12 months. INSYS Therapeutics, Inc. is said to have a 12-month price target set at $8.00. That means that the stock has a strong potential to acquire 7.6% increase from the current trading price.

INSYS Therapeutics, Inc. [NASDAQ:INSY]: Analyst Rating and Earnings

Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For INSYS Therapeutics, Inc. [INSY], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give INSY an Outperform rating. Its stock price has been found in the range of 0.14 to 11.65. This is compared to its latest closing price of $0.34.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for INSYS Therapeutics, Inc. [INSY] is sitting at 2.50. This is compared to 1 month ago, when its average rating was 2.00.

For the quarter ending in Mar-19 INSYS Therapeutics, Inc. [INSY] generated $0.01 billion in sales. That’s 44.98% lower than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Wed 14 Aug (In 62 Days).

Fundamental Analysis of INSYS Therapeutics, Inc. [INSY]

This company’s Return on Total Capital is -39.37, and its Return on Invested Capital has reached 292.20%. Its Return on Equity is -101.95, and its Return on Assets is -34.26. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates INSY financial performance.

Turning to investigate this organization’s capital structure, INSYS Therapeutics, Inc. [INSY] has generated a Total Debt to Total Equity ratio of 342.53. Similarly, its Total Debt to Total Capital is 77.40, while its Total Debt to Total Assets stands at 69.25. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.07, and its Long-Term Debt to Total Capital is 0.02. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.

What about valuation? This company’s Enterprise Value to EBITDA is -0.69. Total Debt to Enterprise Value stands at 4.29. INSYS Therapeutics, Inc. [INSY] has a Price to Book Ratio of 2.02.

This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.20 and its Current Ratio is 1.20. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

INSYS Therapeutics, Inc. [INSY] has 65.50M shares outstanding, amounting to a total market cap of $26.20M. Its stock price has been found in the range of 0.14 to 11.65. At its current price, it has moved down by -96.57% from its 52-week high, and it has moved up 181.69% from its 52-week low.

This stock’s Beta value is currently 3.34, which indicates that it is 126.41% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 30.15. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is INSYS Therapeutics, Inc. [INSY] a Reliable Buy?

Shares of INSYS Therapeutics, Inc. [INSY], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.